FHTX
NASDAQ · Biotechnology
Foghorn Therapeutics Inc
$5.21
+0.21 (+4.20%)
Open$5.20
Previous Close$5.00
Day High$5.36
Day Low$5.06
52W High$6.95
52W Low$2.94
Volume—
Avg Volume118.3K
Market Cap330.40M
P/E Ratio—
EPS$-1.15
SectorBiotechnology
Analyst Ratings
Strong Buy
16 analysts
Price Target
+456.4% upside
Current
$5.21
$5.21
Target
$28.99
$28.99
$18.54
$28.99 avg
$38.99
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 24.08M | 275.09M | 271.86M |
| Net Income | -92,266,448 | 14.43M | 13.33M |
| Profit Margin | -383.2% | 5.2% | 4.9% |
| EBITDA | -101,617,066 | 18.56M | 20.13M |
| Free Cash Flow | — | 14.99M | 11.27M |
| Rev Growth | +157.8% | -4.2% | -6.6% |
| Debt/Equity | — | 0.68 | 0.58 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |